Please try another search
For the nine months ended 31 March 2022, Prestige Biopharma Ltd revenues was not reported. Net loss increased from $8.8M to $93.2M. Higher net loss reflects Other Non-Operating Expense increase from $0K to $71.4M (expense), Operating Expense increase of 83% to $23.1M (expense), Other Non-Operating Income decrease of 77% to $2.5M (income). Basic Earnings per Share excluding Extraordinary Items decreased from -$0.73 to -$7.76.
Period Ending: | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 |
---|---|---|---|---|
Total Revenue | ||||
Gross Profit | 119.97 | |||
Operating Income | -19726.56 | |||
Net Income | -8806.92 | -14353.37 |
Period Ending: | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 |
---|---|---|---|---|
Total Assets | 760898.29 | |||
Total Liabilities | 200851.89 | |||
Total Equity | 560046.4 |
Period Ending: | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 |
---|---|---|---|---|
Period Length: | 0 Months | 0 Months | 0 Months | 0 Months |
Cash From Operating Activities | -2064.75 | |||
Cash From Investing Activities | -22190.87 | |||
Cash From Financing Activities | 44031.43 | |||
Net Change in Cash | -20266.87 | 16611.46 |
Unlock access to over 1000 metrics with InvestingPro
View advanced insights on financial statements, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review